Coherence Neuro

Executive Summary

Coherence Neuro is a San Francisco-based biotech startup founded in 2022 that is pioneering a novel class of therapeutic neurotechnology to manage cancer from within the body. The company's platform leverages internal reprogramming of neural circuits to transform cancer from a terminal illness into a manageable chronic condition. By integrating neuroscience and digital health, Coherence aims to develop implantable or minimally invasive devices that modulate neural activity to suppress tumor growth, enhance immune response, or mitigate treatment side effects. While early-stage with no disclosed funding or pipeline details, the approach represents a paradigm shift in oncology, shifting from systemic therapies to targeted neuromodulation. The company's success hinges on preclinical validation, regulatory pathway clarity, and clinical translation. Given the nascent stage and lack of public data, Coherence Neuro's conviction score is moderate. The concept is scientifically intriguing but unproven, with significant technical and regulatory hurdles. The team's location in a vibrant biotech hub and the innovative angle provide some optimism, but investors will require concrete milestones to de-risk the platform. If successful, Coherence could address large unmet needs in hard-to-treat cancers and chronic pain management.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Seed or Series A Funding Round60% success
• Q2 2027Preclinical Proof-of-Concept Data in Animal Models40% success
• Q3 2027FDA Orphan Drug Designation or Breakthrough Device Designation30% success